Public Employees Retirement System of Ohio Makes New $2.15 Million Investment in Immunocore Holdings PLC Sponsored ADR $IMCR

Posted by Francis Steltz on Sep 7th, 2026

Public Employees Retirement System of Ohio acquired a new position in shares of Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR – Free Report) during the 2nd quarter, Holdings Channel reports. The fund acquired 67,558 shares of the company’s stock, valued at approximately $2,145,000.

Several other institutional investors have also recently added to or reduced their stakes in the business. Leonteq Securities AG acquired a new stake in Immunocore in the 4th quarter worth about $30,000. Harbour Investments Inc. increased its stake in shares of Immunocore by 60.2% during the 4th quarter. Harbour Investments Inc. now owns 1,033 shares of the company’s stock valued at $36,000 after acquiring an additional 388 shares during the last quarter. Rockefeller Capital Management L.P. acquired a new position in shares of Immunocore during the 4th quarter valued at about $47,000. Arax Advisory Partners lifted its holdings in shares of Immunocore by 302.9% during the 4th quarter. Arax Advisory Partners now owns 1,386 shares of the company’s stock worth $48,000 after acquiring an additional 1,042 shares during the period. Finally, GAMMA Investing LLC boosted its position in shares of Immunocore by 202.8% in the second quarter. GAMMA Investing LLC now owns 1,920 shares of the company’s stock worth $61,000 after acquiring an additional 1,286 shares during the last quarter. 84.50% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

IMCR has been the subject of several research reports. Zacks Research cut shares of Immunocore from a “strong-buy” rating to a “hold” rating in a research note on Thursday. Morgan Stanley set a $43.00 price objective on shares of Immunocore in a research report on Friday, August 7th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Immunocore in a report on Friday, July 17th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Immunocore in a research note on Monday, July 13th. Finally, TD Cowen upgraded shares of Immunocore to a “strong-buy” rating in a report on Monday, August 24th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Immunocore has a consensus rating of “Moderate Buy” and an average target price of $56.38.

Check Out Our Latest Report on IMCR

Immunocore Stock Performance

Immunocore stock opened at $36.13 on Monday. The stock has a market cap of $1.86 billion, a P/E ratio of -97.65 and a beta of 0.74. The company has a current ratio of 4.47, a quick ratio of 4.44 and a debt-to-equity ratio of 0.94. The stock has a 50 day moving average of $34.49 and a 200-day moving average of $31.75. Immunocore Holdings PLC Sponsored ADR has a 52 week low of $27.56 and a 52 week high of $40.71.

Immunocore (NASDAQ:IMCR – Get Free Report) last issued its quarterly earnings results on Friday, August 7th. The company reported ($0.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.01). Immunocore had a negative return on equity of 4.54% and a negative net margin of 4.20%. On average, analysts expect that Immunocore Holdings PLC Sponsored ADR will post 0.06 EPS for the current fiscal year.

Immunocore Profile

(Free Report)

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.